Strides Pharma Science Limited is shifting focus to chronic therapies from acute as it seeks to weed out excessive seasonality in its US business and move towards a US revenue target of $400-500m that management has been talking about for some time now but got derailed by COVID-19.
Strides Expects Bhami Tech To Boost CDMO Arm; Former CFO Now MD And Group CEO
“We Are Very Late” With Teriparatide Launch
Strides expects a licensing of Bhami’s formulation technology that enables subcutaneous delivery of biologics to boost associate company OneSource’s CDMO business. Meanwhile, its former CFO has been appointed MD and group CEO amid a US portfolio re-balance
More from Business
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.